explore -WSS

explore

author：knowledge 2025-09-30 22:05:56 - browse：41

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Genentech weighs delaying cancer therapy after drug pricing law

hotspot

WSS

Pharma budget tightening trickles down to Doximity

Genentech weighs delaying cancer therapy after drug pricing law

Steward Health Care expansion into Malta flopped

Pregnancy ages women, but effects reverse after delivery

Genentech weighs delaying cancer therapy after drug pricing law

Where are patients getting their prescriptions for GLP

knowledge

explore

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

TB outbreak tied to bone grafts underscores testing shortcomings

Continuity nursing helped my family in our darkest PICU moments

Pregnancy ages women, but effects reverse after delivery

BioMarin wins approval for gene therapy to treat hemophilia A

Bring on the sabbaticals for nurses

23andMe had bad news about my health. I wish a person had delivered it

Surgeons perform first xenotransplant using CRISPR'd pig kidney

BioMarin wins approval for gene therapy to treat hemophilia A

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

hotspot

Genentech weighs delaying cancer therapy after drug pricing law

Biotech investment managers search for lucrative opportunities

Large hospital system sues Multiplan for low

CRISPR technology availability, affordability needs to be expanded

Erich Jarvis studies song birds to learn about human stuttering

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

hotspot

hotspot

explore

entertainment